• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Non-vitamin K Antagonist Oral Anticoagulant, Warfarin, and ABC Pathway Adherence on Hierarchical Outcomes: Win Ratio Analysis of the COOL-AF Registry
CONCLUSION: This Win Ratio analysis demonstrates the significant benefits of NOACs over warfarin and ABC pathway adherence over nonadherence in reducing the composite outcome in patients with AF.PMID:37625457 | DOI:10.1055/s-0043-1772773
Source: Thrombosis and Haemostasis - August 25, 2023 Category: Hematology Authors: Sukrit Treewaree Gregory Y H Lip Rungroj Krittayaphong Source Type: research

Warfarin faring better: Vitamin K antagonists beat rivaroxaban and apixaban in the INVICTUS and PROACT Xa trials
J Thromb Haemost. 2023 Jul 8:S1538-7836(23)00523-8. doi: 10.1016/j.jtha.2023.06.036. Online ahead of print.ABSTRACTAlthough guidelines give preference to the direct oral anticoagulants (DOACs) over vitamin K antagonists (VKAs) for stroke prevention in most patients with atrial fibrillation (AF), DOACs are not recommended in those with rheumatic heart disease or mechanical heart valves. The results of the INVICTUS trial (Investigation of Rheumatic AF Treatment Using Vitamin K Antagonists, Rivaroxaban or Aspirin Studies), which compared rivaroxaban with a VKA in patients with rheumatic heart disease associated AF, and the PR...
Source: Thrombosis and Haemostasis - July 10, 2023 Category: Hematology Authors: John W Eikelboom Jeffrey I Weitz Source Type: research

A Review of FXIa Inhibition as a Novel Target for Anticoagulation
Hamostaseologie. 2023 Feb;43(1):28-36. doi: 10.1055/a-1984-7021. Epub 2023 Feb 20.ABSTRACTLimitations of vitamin K antagonists as chronic oral anticoagulant therapy have largely been supplanted by direct factor IIa and factor Xa inhibitor oral anticoagulants with similar efficacy but an overall better safety profile, lack of routine monitoring, and very limited drug-drug interactions compared with agents such as warfarin. However, an increased risk of bleeding remains even with these new-generation oral anticoagulants in fragile patient populations, in patients requiring dual or triple antithrombotic therapy, or high bleed...
Source: Hamostaseologie - February 22, 2023 Category: Hematology Authors: Ioannis Koulas Alex C Spyropoulos Source Type: research

Effectiveness and safety of oral anticoagulants in non-valvular atrial fibrillation patients with prior bleeding events: a retrospective analysis of administrative claims databases
ConclusionsIn this real-world analysis of a large sample of NVAF patients with prior bleeding, NOACs were associated with similar or lower risk of stroke/SE and MB vs. warfarin and variable risk of stroke/SE and MB against each other.
Source: Journal of Thrombosis and Thrombolysis - May 17, 2022 Category: Hematology Source Type: research

Short-term non-vitamin K antagonist oral anticoagulants vs. warfarin in preventing device-related thrombosis after left atrial appendage closure
AbstractUp to now we have had few evidences on the Non-vitamin K Antagonist Oral Anticoagulants (NOACs) ’ efficacy and safety in preventing device-related thrombosis (DRT) after percutaneous left atrial appendage closure (LAAC). After LAAC implantation, short-term anticoagulation (NOACs or warfarin) was prescribed. Baseline clinical characteristics, procedural parameters and postoperative follow up data were collected and compared between the two groups. From May 2014 to June 2018, 361 consecutive patients underwent LAAC implantation in our center. 170 patients received warfarin for 45 days at least after LAAC implantat...
Source: Journal of Thrombosis and Thrombolysis - March 5, 2021 Category: Hematology Source Type: research

Efficacy and safety of non-vitamin K anticoagulants and warfarin in patients with atrial fibrillation and heart failure: A network meta-analysis
To recommend the proper anticoagulant drug and its dose for patients with atrial fibrillation (AF) and heart failure (HF), we conducted a network meta-analysis (NMA) to make the comparisons among non-vitamin K antagonist oral anticoagulants (NOACs) and warfarin with regard to efficacy (stroke or systemic embolism) and safety (major bleeding).
Source: Thrombosis Research - August 12, 2020 Category: Hematology Authors: Hao Jin, Kongbo Zhu, Lina Wang, Wangjuan Zhou, Hong Zhi Tags: Review Article Source Type: research

Oral Anticoagulation in the Elderly and Frail.
In conclusion, elderly and frail patients requiring anticoagulation for AF or VTE are at higher risk of adverse outcomes, but also have a higher absolute benefit from OAC. Important practical aspects to improve efficacy and safety in this challenging population are summarized in this overview. PMID: 32000266 [PubMed - as supplied by publisher]
Source: Hamostaseologie - January 29, 2020 Category: Hematology Authors: Bauersachs RM, Herold J Tags: Hamostaseologie Source Type: research

Direct oral anticoagulants and warfarin in patients with cirrhosis: a comparison of outcomes
In conclusion DOACs appear to be a safe alternative to warfarin in patients with mild to moderate cirrhosis. Further studies are warranted to confirm these findings.
Source: Journal of Thrombosis and Thrombolysis - January 7, 2020 Category: Hematology Source Type: research

Pages: 1  2  3  4  5